Antisense News and Research

RSS

Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.

New approach to combat cancer by reactivating natural RNA kill switch

Alternative RNA splicing is like a movie editor cutting and rearranging scenes from the same footage to create different versions of a film.

14 Mar 2025

Review sheds light on the mechanistic role of long non-coding RNAs in liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a global health challenge, affecting nearly 30% of adults worldwide.

28 Feb 2025

First insights into familial ALS in Egypt reveal genetic variations and disease progression

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive degeneration of motor neurons, leading to muscle weakness and eventually death.

18 Feb 2025

Alzheimer’s and Parkinson’s linked to aging brain’s failing waste disposal

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other neurodegenerative diseases—offering hope for targeted therapies to slow or prevent these conditions.

30 Jan 2025

Investigating the impact of CircRNAs on cancer progression and drug resistance

The researcher has given an overview on the regulatory network of extracellular circRNAs in cancer and their impact on cancer drug resistance.

6 Jan 2025

Researchers develop new approach to effectively deliver therapeutics into the brain

Researchers at the Icahn School of Medicine at Mount Sinai have developed an innovative approach - demonstrated in mouse models and isolated human brain tissue - to safely and effectively deliver therapeutics into the brain, providing new possibilities for treating a wide range of neurological and psychiatric diseases.

25 Nov 2024

Why predictive retina models could be the future of IND applications

Discover how retina models are revolutionizing rare disease treatment and accelerating drug development.

From Newcells Biotech 22 Nov 2024

Novel gene therapy holds potential in treating patients with epilepsy

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

9 Oct 2024

New triple-targeting pharmacological tool developed for cancer treatment

A study led by researchers of the Institute of Biomedicine of the University of Barcelona (IBUB) has developed a new pharmacological tool capable of simultaneously administering three oligonucleotide-based drugs, each acting against a different therapeutic target within the cell.

8 Oct 2024

Nanodrug targeting miR-10b shows promise in treating metastatic breast cancer

A new research paper was published in Oncotarget's Volume 15 on August 26, 2024, entitled, "Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties."

29 Aug 2024

Understanding the epigenetic regulation of hepatic stellate cells in NAFLD

Non-alcoholic fatty liver disease (NAFLD) has emerged as a leading cause of chronic liver disease worldwide, affecting approximately 38% of the global population from 2016 to 2019.

25 Jul 2024

Novel antisense therapy targets α-synuclein pathologies in neurodegenerative diseases

TMDU researchers demonstrate proof of concept of antisense nucleic acid therapy to prevent the spread of α-synuclein pathologies in synucleinopathies.

25 Jul 2024

60 years in the making: Nanoparticles revolutionize nucleotide delivery

Researchers trace the 60-year evolution of lipid nanoparticles (LNPs) for nucleic acid delivery, highlighting their potential to revolutionize gene therapy with safer and more effective treatments.

10 Jul 2024

RNA splicing modulation as a precision approach for neuroendocrine cancer treatment

Neuroendocrine tumors, including small cell lung cancer and neuroendocrine prostate cancer, are very aggressive with high chances of spreading.

2 Jul 2024

Antisense RNA acts as a cellular 'booster' for gene expression, study finds

The function of non-coding RNA in the cell has long been a mystery to researchers. Unlike coding RNA, non-coding RNA does not produce proteins – yet it exists in large quantities.

24 Jun 2024

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics

Secarna Pharmaceuticals GmbH & Co. KG (Secarna), a leading independent European antisense drug discovery and development company, and Orbit Discovery Ltd. (Orbit), a leader in the discovery of therapeutic peptide hits, today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.

From Secarna Pharmaceuticals 29 May 2024

Antisense News and Research

New approach to combat cancer by reactivating natural RNA kill switch

Review sheds light on the mechanistic role of long non-coding RNAs in liver disease

First insights into familial ALS in Egypt reveal genetic variations and disease progression

Alzheimer’s and Parkinson’s linked to aging brain’s failing waste disposal

Investigating the impact of CircRNAs on cancer progression and drug resistance

Researchers develop new approach to effectively deliver therapeutics into the brain

Why predictive retina models could be the future of IND applications

Novel gene therapy holds potential in treating patients with epilepsy

New triple-targeting pharmacological tool developed for cancer treatment

Nanodrug targeting miR-10b shows promise in treating metastatic breast cancer

Understanding the epigenetic regulation of hepatic stellate cells in NAFLD

Novel antisense therapy targets α-synuclein pathologies in neurodegenerative diseases

60 years in the making: Nanoparticles revolutionize nucleotide delivery

RNA splicing modulation as a precision approach for neuroendocrine cancer treatment

Antisense RNA acts as a cellular 'booster' for gene expression, study finds

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics

New chemical modification improves effectiveness and safety of ASO therapy for CNS diseases

Study sheds light on the crucial role of glutamate tRNA fragments in brain aging and Alzheimer's disease

Clinical trial shows CRISPR gene editing has exciting potential to treat a rare form of blindness

UK study confirms healthy habits can extend lifespan, even with genetic predispositions

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News